Canadian Cancer Trials Group

This phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The drug is taken by mouth in 28-day cycles. The main goal is to see if the drug can shrink tumors. Researchers …

This phase 3 trial is testing whether adding local ablative therapy (radiation or surgery) to all visible cancer sites, on top of standard hormone therapy, improves outcomes for men with hormone-sensitive prostate cancer that has spread to a few spots (oligometastatic). About 409…

This phase 2 trial compares standard treatment (radiation plus chemotherapy drug cisplatin) against two experimental arms using the immunotherapy drug durvalumab with radiation, followed by either durvalumab alone or durvalumab plus another immunotherapy, tremelimumab. The study …

This phase 2 trial is testing several new combinations of drugs to treat aggressive B-cell lymphoma that has come back or not responded to standard treatment. The study involves 129 participants and compares the new combinations to standard therapy. The main goal is to see if the…

This phase 2 trial is testing whether adding the immunotherapy drug durvalumab to standard trimodality therapy (surgery, chemotherapy, and radiation) helps prevent bladder cancer from coming back. About 82 people with muscle-invasive bladder cancer that hasn't spread are taking p…

This phase 2 trial tests the drug JDQ443 in people with non-small cell lung cancer before they have surgery. The goal is to see if the drug can shrink tumors and improve outcomes. Only 4 participants are enrolled, so results are very early.

This trial tests a vaccine made from two viruses designed to target and kill cancer cells that have a specific protein called MAGE-A3. The viruses are given to 56 adults with advanced solid tumours that no longer respond to standard treatments. The goal is to see if the vaccine i…

This phase 3 trial tests whether adding the experimental drug ipatasertib to standard hormone therapy (fulvestrant) can slow the growth of advanced ER-positive, HER2-negative breast cancer. The study enrolls 250 postmenopausal women whose cancer worsened after initial treatment w…

This phase 2 trial is testing whether combining an experimental pill (CFI-400945) with an immunotherapy drug (durvalumab) can shrink tumors in 15 women with advanced triple negative breast cancer that has spread or cannot be removed. The study measures how many participants see t…

This phase 2 trial tests whether a drug called 177Lu-PSMA-617, which delivers radiation directly to prostate cancer cells, can slow cancer growth better than standard chemotherapy (docetaxel) in 200 men with advanced prostate cancer that has stopped responding to hormone therapy.…

This study tests a new drug given together with standard chemotherapy (R-GDP) for people with aggressive B-cell lymphoma that has come back or not responded to treatment. The main goal is to find the highest dose that is safe and does not cause severe side effects. About 40 adult…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help patients live longer by helping their immune system fight the cancer. Participants m…

This study tests two drugs, sunitinib and temsirolimus, in 137 people with advanced rare cancers that have no cure. The goal is to see if these drugs can shrink tumors or slow their growth. While not a cure, the approach aims to better control the disease and improve survival.

This study compares two types of brachytherapy (radiation placed directly into the prostate) for men with localized prostate cancer. One type uses a high dose of radiation given in two sessions, the other uses low-dose radioactive seeds left in place. The goal is to see how well …

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study tests a new drug called CFI-402257 combined with the standard chemotherapy paclitaxel in people with advanced HER2-negative breast cancer that cannot be cured. The goal is to see if the combination works better than paclitaxel alone at slowing tumor growth. About 37 wo…

This study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…

This study is testing whether giving less radiation to the lymph nodes can reduce side effects for people with low-risk HPV-related throat cancer. The goal is to see if doctors can safely skip radiation to some lymph node areas without increasing the chance of the cancer coming b…

This study looks at the cost-effectiveness of three treatments for chronic lymphocytic leukemia (CLL) in patients aged 65 and older. Researchers compared ibrutinib alone or with rituximab against bendamustine plus rituximab, measuring both healthcare costs and quality of life. Th…